These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26391479)

  • 1. TERT promoter mutations in soft tissue sarcomas.
    Campanella NC; Penna V; Abrahão-Machado LF; Cruvinel-Carloni A; Ribeiro G; Soares P; Scapulatempo-Neto C; Reis RM
    Int J Biol Markers; 2016 Feb; 31(1):e62-7. PubMed ID: 26391479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities.
    Koelsche C; Renner M; Hartmann W; Brandt R; Lehner B; Waldburger N; Alldinger I; Schmitt T; Egerer G; Penzel R; Wardelmann E; Schirmacher P; von Deimling A; Mechtersheimer G
    J Exp Clin Cancer Res; 2014 Apr; 33(1):33. PubMed ID: 24726063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
    Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
    Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
    J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors.
    Cárcano FM; Vidal DO; van Helvoort Lengert A; Neto CS; Queiroz L; Marques H; Baltazar F; da Silva Martinelli CM; Soares P; da Silva EC; Lopes LF; Reis RM
    Tumour Biol; 2016 Apr; 37(4):4901-7. PubMed ID: 26526580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
    Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
    Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.
    Ferreira MSV; Crysandt M; Braunschweig T; Jost E; Voss B; Bouillon AS; Knuechel R; Brümmendorf TH; Beier F
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
    Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
    Ko E; Seo HW; Jung ES; Kim BH; Jung G
    Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.
    Mosrati MA; Willander K; Falk IJ; Hermanson M; Höglund M; Stockelberg D; Wei Y; Lotfi K; Söderkvist P
    Oncotarget; 2015 Sep; 6(28):25109-20. PubMed ID: 26298771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
    Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
    Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between functional TERT promoter polymorphism rs2853669 and cervical cancer risk in South Indian women.
    Vinothkumar V; Arun K; Arunkumar G; Revathidevi S; Ramani R; Bhaskar LVKS; Murugan AK; Munirajan AK
    Mol Clin Oncol; 2020 May; 12(5):485-494. PubMed ID: 32257207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
    Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
    Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
    Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
    Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutations in clear cell renal cell carcinoma.
    Hosen I; Rachakonda PS; Heidenreich B; Sitaram RT; Ljungberg B; Roos G; Hemminki K; Kumar R
    Int J Cancer; 2015 May; 136(10):2448-52. PubMed ID: 25331263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
    Ofner R; Ritter C; Heidenreich B; Kumar R; Ugurel S; Schrama D; Becker JC
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):613-617. PubMed ID: 27990595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.
    Griewank KG; Schilling B; Murali R; Bielefeld N; Schwamborn M; Sucker A; Zimmer L; Hillen U; Schaller J; Brenn T; Schadendorf D; Mentzel T
    Mod Pathol; 2014 Apr; 27(4):502-8. PubMed ID: 24030750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of single-nucleotide polymorphism in TERT promoter on follicular thyroid tumor development.
    Hirokawa T; Arimasu Y; Nakazato Y; Chiba T; Fujiwara M; Kamma H
    Pathol Int; 2020 Apr; 70(4):210-216. PubMed ID: 31943533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.